Jump to content

New Psoriasis Drug Wins FDA Approval

Recommended Posts

  • Chief Cushie

I know a lot of us have said we have psoriasis...


New Psoriasis Drug Wins FDA Approval


.c The Associated Press


WASHINGTON (AP) - A new drug for the itchy-skin condition psoriasis won the Food and Drug Administration's approval Monday.


Raptiva was developed by the companies Genentech and Xoma and is an antibody intended for treatment of moderate to severe psoriasis in people at least 18 years old.


Genentech spokeswoman Tara Cooper said the drug should be available by Thanksgiving. She said the average patient would pay more than $14,000 annually for weekly injections of the drug.


The chronic skin condition is thought to form when the immune system runs amok and cells called memory effector T cells prompt skin inflammation. The condition, characterized by inflamed skin with scaly patches, affects about 1.5 million Americans.


Raptiva, known by the technical name efalizumab, is intended to keep the T-cells that cause the inflammation from binding to other cells in the skin.


The National Psoriasis Foundation said clinical trials found side effects of the drug included moderate flu-like symptoms with the first few doses and occasional headache, chills, upset stomach and fever.


In January the FDA approved another new treatment for psoriasis called Amevive, also designed to target the T-cells involved in development of the condition.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...